Prestige Consumer Healthcare presents a mixed fundamental picture: a resilient, asset-light consumer health portfolio generates robust cash flows (cumulative OCF exceeded net income by 34% over ten quarters), yet recent quarters reveal persistent top-line pres...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.98+9.6% vs $0.89 | $266M+5.0% vs $253M |
Q2 2026 May 13, 2026 | $1.23-11.5% vs $1.39 | $282M-4.1% vs $294M |
Q1 2026 Feb 5, 2026 | $1.14-1.7% vs $1.16 | $283M+0.4% vs $282M |
Q4 2025 Nov 6, 2025 | $1.07+10.3% vs $0.97 | $274M-6.8% vs $294M |
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, President, & CEO and Christine Sacco, CFO and COO will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, September 10, 2026 at 12:45 p.m.
National survey commissioned by DenTek, the #1 OTC dental guard brand for nighttime teeth grinding, finds nearly 8 in 10 football fans keep thinking about the game after it ends, with many reporting stress-related behaviors that extend into bedtime. NFL legends Ronde & Tiki Barber join DenTek to encourage fans to recognize when football stress may be affecting more than just game day.
Benchmark PBH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Prestige Consumer Healthcare Inc. (PBH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $45.92 | $2.18B | 11.74 | -4.31% | 17.48% | 10.22% | — | |
| $86.48 | $2.01B | 22.40 | -5.23% | 2.77% | 4.18% | — | |
| $96.03 | $22.75B | 31.80 | 1.57% | 11.96% | 17.78% | — | |
| $22.00 | $1.51B | 6.63 | 2.28% | 2.73% | 47.41% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $2.64 | $2.32B | -3.77 | -1.46% | -10.47% | -17.03% | — |
Prestige Consumer Healthcare Inc. (PBH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Prestige Consumer Healthcare Inc. (PBH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 6, 2026·SEC
Jul 15, 2026·SEC
Get notified when PBH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Prestige Consumer Healthcare Inc. (PBH) stock FAQ — growth, dividends, profitability & financials explained
Prestige Consumer Healthcare Inc. (PBH) reported $1.10B in revenue for fiscal year 2026. This represents a 12666% increase from $8.7M in 2001.
Prestige Consumer Healthcare Inc. (PBH) saw revenue decline by 4.3% over the past year.
Yes, Prestige Consumer Healthcare Inc. (PBH) is profitable, generating $172.0M in net income for fiscal year 2026 (17.5% net margin).
Prestige Consumer Healthcare Inc. (PBH) has a return on equity (ROE) of 10.2%. This is reasonable for most industries.
Prestige Consumer Healthcare Inc. (PBH) generated $235.4M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
